Eyenovia, Inc. announced on October 23, 2024, the publication of a study in the Journal of Ocular Pharmacology and Therapeutics. The study demonstrated the favorable impact of medication delivered with the Optejet on the ocular surface.
The publication highlights the Optejet's ability to achieve a therapeutic dose of medication with significantly less exposure to harmful preservatives. This is a key differentiator for the company's proprietary drug delivery platform.
Additionally, a presentation at the American Academy of Optometry summarized a Phase 4 study of Mydcombi. This study showed that clinically relevant mydriasis can be achieved with a half-dose per eye when delivered via the Optejet.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.